Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Eagle Asset Management Inc.

Eagle Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 309,589 shares of the biopharmaceutical company’s stock after acquiring an additional 63,385 shares during the quarter. Eagle Asset Management Inc. owned about 0.24% of Alnylam Pharmaceuticals worth $85,889,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth about $26,000. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $42,000. Finally, Friedenthal Financial acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $51,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:ALNY opened at $247.05 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company’s 50 day moving average is $273.54 and its two-hundred day moving average is $236.84. The company has a market cap of $31.86 billion, a PE ratio of -94.29 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the business earned $1.15 earnings per share. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent analyst reports. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $198.00 to $370.00 in a report on Friday, August 16th. Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.